POINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer
January 15th 2018ASCO clinical practice guidelines recommend resection followed by treatment with gemcitabine and capecitabine as the standard of care; however, neoadjuvant therapy is also considered an appropriate alternative.